Your Global Leader in Stem Cell Market Research
Edinburgh, UK, December 7, 2016 – Precious Cells is offering their employees the ultimate employee benefit unlike anything ever seen before. They will cryogenically store employees’ and their loved ones’ stem cells, for free. This means they can be used in treatment for life threatening conditions today, tomorrow and in the future. [Read more…]
One of the ways to use market intelligence to analyze trends within the mesenchymal stem cell (MSC) market is to assess how the cell type is being discussed on leading social media platforms, such as Twitter.
Twitter.com is one of the most widely used social media platforms today. It has with 316 million monthly active users and 500 million Tweets sent per day, according to Twitter’s company statistics.
It is also the 9th most visited website in the world, an impressive accomplishment.
The figure below shows a hashtag map for the term “#mesenchymal.” It was produced using the social analytics platform Hashtagify.me.
The linked topics shown as spokes in this figure represent the top hashtags that are used together with the hashtag “#mesenchymal” on Twitter.
[Read more…]
Each year, companies must decide on the best stem cell conferences and events to attend, among the dozens that are offered across North America, Europe, Asia, and to a lesser degree, other regions worldwide. This is a major decision, because attending stem cell conferences requires a significant investment of time, energy, and resources.
Therefore, this post is your guide to identifying some of the top stem cell conferences worldwide.
In late 2015, the BioInformant team attended the World Stem Cell Summit in Atlanta, GA, which was an incredible stem cell conference. This year in 2016, the stem cell conference is being held in West Palm Beach, FL, on December 6-9, 2016.
The event features 1,200 attendees representing from more than 40 countries. Impressively, there are also up to seven speaker tracks occuring at a time. Because of the shear volume of the content being shared, you can choose targeted content suited to your specific interests.
In addition to the concurrent speaker tracks, there are also Expert Luncheon Roundtables, Investor Presentations, a Stem Cell Actions Award Dinner, and 1-on-1 networking opportunities.
For this reason, the World Stem Cell Summit event gets our honor of being the “Top Stem Cell Conference of the Year.” It is an event that I highly recommend that every stem cell industry participant experience at least once in their lifetime.
To learn more about this event, click here to see the Top 10 Quotes from Day 1 of the conference or Gems Shared During Day 2.
RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation. In today’s announcement, RoosterBio announced that it has entered into a Cooperative Research and Development Agreement (CRADA) that will enable “collaborative development of innovative stem cell-based therapies related to wounded warrior injuries and rehabilitation.” [Read more…]
This week stem cell industry participants announced major collaborations, patent awards, research advances, and more. Check out our stem cell industry coverage below and let me know what you think. Enjoy!
This is an exclusive interview with Dr. Paul Wotton, who joined Cynata Therapeutics (ASX: CYP) Board of Directors in June of 2016. Cynata is an Australian company that is developing a therapeutic stem cell platform technology originating from the University of Wisconsin-Madison that utilizes iPSCs are starting material for generating nearly unlimited quantities of MSCs. Dr. Wotton was previously President and CEO of Ocata Therapeutics, joining the company in July 2014 and managing it through an all-cash take-over by Atellas Pharma valued at $379 million.
Boston biotech company ORIG3N has announced a collaboration with South Korea’s Kangstem Biotech in a joint effort to gain insight into the effectiveness of induced neural stem cells (iNSC) in disease modeling. As a pioneer of regenerative medicine, ORIG3N is leading the way towards the future of medicine by crowdsourcing blood samples to create the world’s largest and most diverse biorepository of stem cells. As part of this collaboration, Kangstem Biotech will be providing iNSC’s to ORIG3N for research.
Cellular Dynamics International (CDI), a FUJIFILM company, announced that it has entered into a Cooperative Research and Development Agreement with the National Eye Institute, a division of the NIH, to conduct research to advance a cell transplantation therapy for the treatment of retinal degenerative disease using retinal pigment epithelium derived from induced pluripotent stem cells (iPSC-RPE). The collaboration includes the joint development of an optimized biocompatible biodegradable scaffold that is likely to be a critical component for a potential future therapy.
Commence Bio announced that the company has received its first patent for MSC1.
Commence Bio is a pre-clinical stage biotechnology company that is based on the concept that cancer and other inflammatory conditions can be addressed by “rebooting patients’ immune systems” with a new class of medicinal stem cells, MSC1 and MSC2. The company is now developing a therapeutic pipeline, as well as offering research products that include MSC1 and MSC2 cells and media.
A characteristic that can distinguish one cord blood bank from another is the amount of its quality guarantee. Currently, the top cord blood banks in the U.S offer quality guarantee packages that range from $25,000 – $90,000, with Americord topping that list at $90,000. Interestingly, Americord raised its guarantee from $80,000 to $90,000 in mid-2014 to further separate itself from the competition and increase its trustworthiness in the eyes of its clients. The primary reason for a cord blood bank to offer a quality guarantee is to reassure prospects that banking their children’s cord blood is a protected investment.
As of July 2016, our highest-demand market report is “Mesenchymal Stem Cells – Advances & Applications.” You should view it because: 1) MSCs are one of the fastest growing areas of stem cell research, 2) MSCs are now more frequently cited than any other stem cell type within the scientific literature, and 3) Google Trend data shows MSC searches to be approximately twice as common as the next most common adult stem cell type. The market for MSCs is growing. Are you informed about market opportunities and ready to act on them now?
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.
